FDA Rips Compounders Making Unapproved J&J Drug
The U.S. Food and Drug Administration on Tuesday released warning letters sharply criticizing two compounding pharmacies for allegedly producing a version of Johnson & Johnson gastrointestinal drug Motilium despite its lack...To view the full article, register now.
Already a subscriber? Click here to view full article